Greenwich Life rises on data from late-stage trial for breast cancer vaccine

Devonyu/iStock via Getty Images Greenwich LifeSciences ( NASDAQ: GLSI ) added ~23% in the premarket on Wednesday after the company posted preliminary immune response data from a Phase 3 clinical trial for GLSI-100, a vaccine designed to prevent the recurrence of breast cancer. The FLAMINGO-01 trial enrolled.